Early CDK4/6 inhibitors are not inferior to chemotherapy in HR+/HER2- metastatic breast cancer
Seemingly disappointing survival findings in the final results from the PEARL study are balanced by better quality of life with combination therapy
Phase III data highlight the promise of antibody–drug conjugates in metastatic breast cancer
Significant progression-free survival benefits in pre-treated HER2-positive metastatic disease reported in the DESTINY-BREAST03 and SYD985.002/TULIP trials
Early-stage HER2+ breast cancer may benefit from de-escalated treatment, but biomarkers are still required
Findings from three studies highlight that selecting patients for de-escalated treatment is still challenging
Early and relapsed TNBC is no longer so negative
Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent
BrighTNess trial: no benefit from the addition of veliparib to neoadjuvant chemotherapy in TNBC
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Cancer Research
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi